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Introduction
During mammalian embryogenesis, early embryonic 
cells progressively diﬀ  erentiate from a pluripotent state 
into distinct cell lineages. Concomitantly, they gradually 
lose their developmental potential [1]. Pluripotency, 
which is a characteristic of cells in the inner cell mass 
(ICM) of the preimplantation blastocyst, is deﬁ  ned as the 
ability of a cell to diﬀ  erentiate into all of the cell types of 
an organism. Th  e state of pluripotency is transient in 
vivo; however, embryonic stem cells (ESCs) derived from 
the ICM of the blastocyst can maintain pluripotency 
indeﬁ  nitely in vitro. Pluripotency has been shown to be 
controlled through an extensive transcriptional network. 
Remarkably, diﬀ   erentiated somatic cells can be repro-
grammed to a pluripotent state by the overexpression of 
deﬁ  ned transcription factors (Oct4/Sox2/Klf4/c-Myc or 
Oct4/Sox2/Nanog/Lin28) [2,3]. Among these transcrip-
tion factors, Oct4 plays a key role in both maintaining 
and re-establishing pluripotency.
Oct4 (encoded by Pou5f1, also known as Oct3, Oct3/4) 
was ﬁ  rst  identiﬁ   ed in mice as an ESC-speciﬁ  c  and 
germline-speciﬁ  c transcription factor [4-6]. In humans, 
OCT4 is the product of the OTF3 gene, and three 
isoforms,  OCT4A, OCT4B  and OCT4B1, have been 
reported [7]. Among these isoforms, only OCT4A –
which shares 87% amino acid sequence identity with 
mouse Oct4 – has been demonstrated able to maintain 
stemness in pluripotent stem cells; it is referred to as 
OCT4 in the vast majority of reports. Th   e Oct4 protein 
comprises three domains: a central POU (Pit-Oct-Unc) 
domain for DNA binding, an N-terminal transactivation 
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cell type-speciﬁ  c transactivation domain. Oct4 belongs 
to the POU transcription factor family, in which the 
members control the expression of their target genes 
through binding an octameric sequence motif of an 
AGTCAAAT consensus sequence [8].
During mouse embryonic development, Oct4 is highly 
expressed in pluripotent embryonic cells, as well as cells of 
the germline, and its expression rapidly decreases upon 
diﬀ  erentiation. Analysis of upstream regulatory elements 
of the Oct4 genomic locus identiﬁ  ed a proximal enhancer 
and a distal enhancer, in addition to a TATA-less proximal 
promoter [9]. Interestingly, the proximal enhancer and the 
distal enhancer function at diﬀ  erent developmental stages: 
the proximal enhancer functions in the epiblast and 
epiblast stem cells, while the distal enhancer plays roles in 
the ICM, primordial germ cells and ESCs. Nordhoﬀ   and 
colleagues compared human, bovine and murine Oct4 
upstream sequences and found four conserved regions 
(CR1 to CR4), showing possible involvement in Oct4 
expression [10]. For more details on this topic, we refer 
readers to several excellent reviews [11,12].
Functionally, Oct4 is essential for early embryonic 
development, although it is not required for mouse 
somatic stem cell self-renewal [13]. In the absence of 
Oct4, embryos die at the time of implantation because of 
a lack of pluripotent ICM cells [14]. Oct4 is therefore 
considered a master regulator for the initiation and 
maintenance of pluripotent cells during embryonic 
development. Interestingly, the precise expression level 
of Oct4 is a critical determinant of ESC fates, and their 
pluripotent potential can be sustained only when the 
Oct4 expression level is maintained within a normal 
range [15-17]. Reducing Oct4 expression by one-half 
induces ESCs to diﬀ  erentiate into trophoblasts, while less 
than twofold overexpression of Oct4 triggers ESC 
diﬀ  erentiation into primitive endoderm and mesoderm 
[17]. In line with this, transforming growth factor beta-
induced transient Oct4 upregulation can promote 
cardiac mesoderm diﬀ  erentiation, supporting the role of 
the level of Oct4 in regulating pluripotency and diﬀ  er-
entiation [18]. Moreover, the recent discovery of an 
essential role of Oct4 in reprogramming somatic cells 
into pluripotent cells further highlights its irreplaceable 
function in establishing pluripotency.
In the present review, we ﬁ   rst summarize recent 
progress in understanding how the regulation of Oct4 
expression is achieved at multiple levels, and then 
describe how Oct4 acts with its partners to regulate the 
expression of its target genes in maintaining pluripotency. 
Finally, we brieﬂ  y review the role of Oct4 in regaining 
pluripotency. Owing to limitations of space, we cannot 
cover all related studies and apologize to the authors 
whose contributions are not mentioned in this review.
Tight control of Oct4 expression at multiple levels
Achieving precise control of Oct4 expression is a key 
issue for the maintenance of as well as the re-establish-
ment of pluripotency, and many players participate in 
this process at multiple levels (Figure 1). First, a deﬁ  ned 
chromatin state is essential for Oct4 expression. In un-
diﬀ  erentiated ESCs, the Oct4 locus is hypomethylated 
and packaged with nucleosomes containing highly acetyl-
ated histone H3 (Lys 9, Lys 14) and dimethylated or 
trimethylated histone H3 (Lys 4) [19]. Th   e locus, however, 
undergoes a series of epigenetic modiﬁ  cations, leading to 
the repression of Oct4 expression upon the induction of 
diﬀ   erentiation. In addition to deacetylation, G9a-
mediated histone H3 methylation on Lys 9 recruits hetero-
chromatin protein 1 to confer a compact chroma  tin 
conﬁ  guration [19]. Subsequently, permanent inactiva  tion 
of Oct4 is achieved when two de novo methyl  transferases, 
Dnmt3a and Dnmt3b, function synergistically to methylate 
the promoter of Oct4  [20]. In addition, Cdk2ap1 was 
shown to promote Oct4 promoter methylation and to 
downregulate Oct4 expression during mouse ESC diﬀ  er-
en  tiation through its direct interaction with the methyl 
DNA-binding protein Mbd3 [21]. Additionally, Paf1C, a 
component of the Paf1 complex, associates with RNA 
polymerase II and binds to the promoter of Oct4 to 
maintain a transcriptionally active chromatin structure 
[22]. Th  e epigenetic regulation of the chromatin state 
therefore plays an important role in the control of Oct4 
expression and the proper reprogramming of somatic 
cells to overcome repressive modiﬁ  cations.  Indeed, 
inhibitors of G9a and DNA methyltransferase have been 
shown to promote the reprogramming eﬃ   ciency  in  a 
variety of cell types [23].
At the transcriptional level, direct binding of trans-
acting regulators to the Oct4 locus also plays a critical 
role in the modulation of Oct4 expression. Several 
members of the orphan nuclear receptor family have 
been recently found to participate in the control of Oct4 
expression, supporting an earlier report that the nuclear 
receptors PAR-1/COUP-TFII, EAR-3/COUP-TFI and 
RAR/RXR regulate the Oct4 promoter activity in mouse 
embryonal carcinoma cells [24]. Steroidogenic factor-1 
and estrogen-related receptor b (Esrrb) were shown to 
directly activate the transcription of human OCT4 and 
mouse Oct4, respectively, to sustain pluripotency in ESCs 
[25,26]. Another orphan nuclear receptor, LRH-1 (also 
known as Nr5a2), was shown to bind the steroidogenic 
factor-1 responsive element in the proximal promoter 
and the proximal enhancer of Oct4 to maintain Oct4 
expression at the epiblast stage of embryonic develop-
ment [27]. Additionally, germ cell nuclear factor represses 
Oct4 expression by speciﬁ  cally binding with the proximal 
promoter and is necessary for conﬁ  ning Oct4 expression 
to the germline [28]. Interestingly, the orphan nuclear 
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repressor of Oct4 expression depending on its phos-
phory  lation, sumoylation and associated coregulators 
[29,30]. Furthermore, pluripotency factors form a regula-
tory circuitry consisting of autoregulatory and feed-
forward loops [31,32]. For instance, the distal enhancer of 
Oct4 has a composite Oct–Sox element, and Oct4 and 
Sox2 bind to this element to synergistically activate the 
expression of Oct4 [33]. Sall4, a spalt family member, also 
modulates ESC pluripotency through transcriptional 
control of Oct4 [34,35]. Th   e coordinated action of these 
key factors is therefore fundamental for the maintenance 
of pluripotency.
miRNAs play important roles in the post-trans  crip-
tional regulation of Oct4 expression. Xu and colleagues 
reported that miR-145 directly repressed the 3’ untrans-
lated region of OCT4 mRNA during human ESC 
diﬀ   erentiation. Interestingly, the promoter of miR-145 
was also observed to be bound and inhibited by OCT4 in 
human ESCs, uncovering a double-negative feedback 
loop for OCT4 and miRNA expression [36]. Although 
miRNAs usually target the 3’ untranslated regions of 
mRNAs, miR-296, miR-470 and miR-134 were found to 
be upregulated in diﬀ   erentiated mouse ESCs and to 
target the coding sequences of Oct4, Nanog and Sox2 in 
various combinations [37]. In addition to these negative 
regulators of Oct4 during ESC diﬀ  erentiation, Qiu and 
colleagues recently found that Lin28 – which is a 
repressor of miRNA processing – bound OCT4 mRNA 
directly within its coding region and recruited RNA 
helicase A to promote the translation of OCT4 in human 
ESCs [38]. Th  ere may still be many other regulators 
functioning at the post-transcriptional level that remain 
to be found.
Th   e stability and activity of Oct4 proteins are subject to 
modiﬁ   cations at the post-translational level. An early 
study suggested that the diﬀ  erential phosphorylation of 
Oct4 might aﬀ  ect the transactivation ability of the Oct4 
carboxyl-terminal transactivation domain [39]. A recent 
study reported that human OCT4 can be modiﬁ  ed by the 
monosaccharide O-linked β-N-acetylglucosamine 
(O-GlcNAc), which regulates the activity of a wide 
variety of cellular proteins [40]. Notably, the enzyme 
catalyz  ing this post-translational reaction, Ogt, was 
found in Oct4-associated protein complexes in two 
recent independent studies [41,42]. Whether this modiﬁ  -
cation regulates the OCT4 activity in ESCs, however, 
remains unclear. Moreover, ubiquitination is a common 
modiﬁ  cation of proteins that decreases the stability of 
modiﬁ  ed proteins. Our laboratory ﬁ  rst identiﬁ  ed a mouse 
HECT-type E3 ubiquitin ligase of Oct4 known as Wwp2 
[43]. Subsequent research indicated that Wwp2 plays an 
important role in Oct4 ubiquitination and degradation 
during the diﬀ  erentiation of embryonic carcinoma cells, 
Figure 1. Precise control of Oct4 expression at multiple levels. 
The chromatin modifi  er Paf1C increases Oct4 expression by relaxing 
the compact chromatin, while G9a adds a repressive mark and 
recruits heterochromatin protein 1 (HP1), leading to a compact 
chromatin confi  guration. Subsequently, Dnmt3a/b methylates the 
Oct4 promoter to permanently inactivate Oct4 expression. This 
process is enhanced by Cdk2ap1 interacting with Mbd3. At the 
transcription level, two sets of transcription factors and nuclear 
receptors function antagonistically: one set (including Esrrb, LRH-1, 
Oct4, Sox2 and Sall4) activates Oct4 expression, while the other 
set (including germ cell nuclear factor (GCNF) and Tr2) represses 
its expression. After transcription, Lin28 recruits RNA helicase A to 
promote the translation of Oct4 mRNA, while miRNAs (including 
miR-134 and miR-470) cause its decay. In addition, several post-
translational modifi  cations (such as ubiquitination (Ub), sumoylation 
and phosphorylation (P)) are added to the Oct4 protein after it is 
translated and infl  uence the activity and stability of Oct4 proteins. 
SUMO, small ubiquitin-related modifi  er.
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in undiﬀ   erentiated mouse embryonic carcinoma cells 
and ESCs [44]. Interestingly, its human counterpart, 
WWP2, can ubiquitinate endogenous OCT4 proteins in 
human ESCs and promote its degradation through the 
26S proteasome [45]. Currently, there exists no deﬁ  nitive 
answer to the question of why this enzyme degrades 
OCT4 proteins in undiﬀ  erentiated human ESCs but not 
in undiﬀ  erentiated mouse ESCs. One possible explana-
tion is that human ESCs represent a more developed 
stage than mouse ESCs [46]. In addition to ubiquitination, 
our group and another group found that Oct4 was a 
target of small ubiquitin-related modiﬁ  er-1 modiﬁ  cation 
and that the sumoylation resulted in increased stability, 
DNA binding and transactivation of Oct4 [47,48]. 
Ubiquitination and sumoylation appear to jointly control 
Oct4 proteins at an appropriate level in ESCs. We hypo-
thesize that other types of modiﬁ  cations of Oct4 proteins 
may exist to regulate its protein level and function.
Th  e Oct4 expression level is modulated by multiple 
factors and mechanisms. Continued eﬀ  orts are required 
to elucidate the sophisticated regulatory network asso-
ciated with the precise control of Oct4 expression, 
particu  larly to understand how Oct4 expression is 
reactivated during reprogramming.
Transcriptional targets and protein complexes 
associated with the function of Oct4
Oct4 lies at the center of the mechanisms that maintain 
the self-renewal and pluripotency of ESCs. Oct4 mainly 
functions through the activation of pluripotency-
associated and self-renewal-associated genes, while 
simul  taneously repressing genes that promote diﬀ  eren-
tiation, in coordination with other pluripotency factors 
and coregulators. Genome-wide mapping of the binding 
sites of Oct4 and other ESC factors has revealed that 
Oct4 clusters with diﬀ  erent but overlapping sets of trans-
criptional factors or coregulators at distinct genomic 
locations, suggesting that the function of Oct4 in the 
regulation of gene expression may be modulated by 
various associated partners. Among the partners of Oct4, 
Sox2 is the best characterized. Th   ey are considered as a 
versatile pair of master regulators orchestrating self-
renewal and pluripotency. Th  e regulatory elements of a 
large number of Oct4 target genes contain a composite 
Oct–Sox element separated by several nucleotides. Oct4 
and Sox2 bind the element simultaneously and syner-
gistically activate the expression of these genes, including 
Oct4 [33], Sox2 [33], Nanog [49], Fgf4 [50], Utf1 [51] and 
Zfp206 [52], all of which play important roles in main-
taining pluripotency. Subsequent studies have shown that 
certain Oct4/Sox2-targeted transcription factors are 
themselves often components of the Oct4 interactome. 
For instance, Oct4, Sox2 and Nanog have been 
con  sidered to act as a core transcriptional regulatory 
circuitry in pluripotent stem cells, as they co-occupy a 
large number of their target genes [31,53,54]. Nanog 
could be an important target for Oct4 in maintaining 
pluripotency; it is required for repressing the diﬀ  er-
entiation of pluripotent epiblast cells toward extraembry-
onic lineages [49,55,56], and its overexpression can 
maintain ESCs in an undiﬀ  erentiated state in the absence 
of leukemia inhibitory factor. Additionally, Zfp206 was 
recently demonstrated to physically interact with Oct4/
Sox2, being a key component of Oct4/Sox2 complexes 
[57]. Th  e Oct4 transcriptional regulatory circuitry thus 
ensures tight control of pluripotency regulator expression 
and maintains ESCs in an undiﬀ  erentiated state.
Several well-known Oct4 target genes – including Fgf4, 
Utf1,  Osteopontin,  Rex1,  Hand1 and α and β human 
chorionic gonadotropin (hCG) – were identiﬁ  ed through 
earlier single-gene experiments using promoter-reporter 
or enhancer-reporter activity assays (reviewed in [11,12]). 
To identify Oct4 targets at a global level, high-throughput 
approaches such as gene-expression proﬁ  ling in Oct4-
manipulated mouse ESCs, genome-wide chromatin 
immuno  precipitation assays or a combination of both 
have been utilized in the past several years [32,58,59]. 
Th  ese investigations identiﬁ  ed hundreds and thousands 
of putative Oct4 targets. Notably, Oct4 appears to 
function predominantly as an activator of gene expres-
sion, although it also suppresses transcription [59]. 
Interestingly, Matoba and colleagues discovered a group 
of targets that exhibit both activation and suppression 
depending on the Oct4 expression level [58]. Rex1 is an 
example of this unique type of regulation, as at both low 
and high levels Oct4 represses Rex1 expression but at 
intermediate levels it activates Rex1 expression. Th  is 
ﬁ   nding may be related to mechanisms underlying the 
requirement to keep the Oct4 level within a narrow range 
for the main  tenance of ESCs in a self-renewal and 
pluripotent state [17]. In addition to mouse ESCs, 
chromatin immuno  precipitation-on-chip experiments 
have also been performed in human ESCs to reveal DNA-
protein binding events involving OCT4, SOX2 and 
NANOG. Th  e target genes identiﬁ  ed frequently encode 
transcription factors, many of which are developmentally 
important homeodomain proteins [31]. Moreover, 
Chavez and colleagues reported the identiﬁ  cation of a 
core OCT4 regulatory network in human ESCs consisting 
of 33 target genes by carrying out an integrated analysis 
of high-throughput data [60]. More recently, two groups 
reported the genome-wide identiﬁ  cation of binding sites 
of diﬀ  erent sets of ESC factors [61,62]. Th   eir results show 
that genes in which the promoters are occupied by 
multiple factors, such as Oct4, Sox2, Nanog and Klf4, are 
generally active in ESCs; in contrast, genes that bind 
fewer or single factors tend to be inactive or repressed 
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pluripotency are therefore orchestrated by the co-
ordinated eﬀ  orts of many key transcriptional factors and 
coregulators.
In addition to activating pluripotency factors, Oct4 also 
prevents the diﬀ  erentiation of pluripotent cells by acting 
as a repressor of lineage-speciﬁ  c transcription factors. 
During the ﬁ  rst cell fate-deciding event in mammalian 
development – the segregation of the ICM and the 
trophectoderm – Oct4 is required for establishing the 
pluripotency of ICM cells. Oct4 forms a repressive 
complex with and inhibits the transcription of Cdx2, a 
trans  cription factor essential for trophectoderm speciﬁ  -
cation [63]. In the absence of Oct4, the embryo develops 
to the blastocyst stage and appears to be morphologically 
normal. Th   e cells in the ICM, however, diﬀ  erentiate into 
trophoblast cells without pluripotent embryonic cells 
[14]. Moreover, Oct4 recruits a histone H3 (Lys 9) 
methyl  transferase, Eset, to silence the expression of 
trophoblast-associated genes, thus partnering with an 
epigenetic regulator to restrict extraembryonic tropho-
blast lineage potential in ESCs [64]. At the late blastocyst 
stage, Oct4, Sox2 and Nanog are required for the 
development of pluripotent epiblast cells and the restric-
tion of the formation of primitive endoderm. A recent 
study by our group demonstrated that Oct4, together 
with Sox2 and Nanog, directly inhibits the expression of 
Stk40, an inducer of extraembryonic endoderm in mouse 
ESCs. In agreement with the notion that Oct4 functions 
to prevent ICM cells from diﬀ  erentiating into primitive 
endoderm, we found that ESCs depleted of Oct4 by 
speciﬁ  c interfering RNA were mainly incorporated into 
the extra embryonic endodermal lineages in chimeric 
embryos when injected into preimplantation blastocysts 
[16]. Furthermore, it was reported that Oct4 interacts 
with the DNA-binding domain of FoxD3 and represses 
its activation of FoxA1 and FoxA2, two critical regulators 
for the development of the endodermal foregut [65]. Th  e 
subsequent identiﬁ  cation of Oct4-interacting proteins by 
aﬃ   nity puriﬁ  cation and mass spectrometry revealed that 
Oct4 associated with unique transcriptional repression 
complexes containing Hdac1/2 and Mta1/2 in mouse 
ESCs [66,67], providing signiﬁ   cant insight into the 
mechanism of the repression of developmental genes by 
Oct4.
Recently, using improved aﬃ   nity tagging approaches, 
van den Berg and colleagues and Pardo and colleagues 
identiﬁ  ed 50 and 92 putative Oct4-associated proteins, 
respectively, in mouse ESCs [41,42]. Th  ese two studies 
not only identiﬁ   ed more detailed Oct4-centered 
interactome networks than previous analyses, but also 
detected interactions between Oct4 and signaling path-
ways. For example, van den Berg and colleagues found 
that Oct4 associated with Rbpi, the nuclear eﬀ  ector of 
the Notch signaling pathway – implying a connection 
between Oct4 and the Notch-regulated gene expression. 
In addition, both interactomes contain chromatin-
modifying complexes, such as NuRD and SWI/SNF, 
repre  senting links between epigenetic modify  ing com-
plexes and pluripotency transcriptional factors. Despite 
substantial progress in understanding Oct4-centered 
protein interactomes in ESCs, there are signiﬁ    cant 
discrepancies between these two studies [68]. Further 
investigation and detailed comparison are required to 
clarify the basis of the diﬀ  erences.
In addition to protein coding genes, noncoding RNA 
targets of Oct4 have been found. For example, in concert 
with Sox2, Oct4 positively regulates miR-302, a cluster of 
eight miRNAs expressed speciﬁ   cally in ESCs. One 
member of this cluster, miR-302a, inhibits the translation 
of cyclin D1 (an important G1 regulator) to maintain an 
ESC-speciﬁ   c cell cycle proﬁ   le [69]. Moreover, a long 
noncoding RNA, AK028326, which was recently shown 
to be directly activated by Oct4, was observed to function 
as a coactivator of Oct4 in a regulatory feedback loop 
[70]. Functionally, the overexpression or knockdown of 
AK028326 changed the expression levels of pluripotency 
factors, as well as lineage-speciﬁ  c factors, indicating its 
functional role in determining the cell fate of ESCs. In 
addition, Oct4 also functions during X-chromosome 
reprogramming. It can directly binds Tsix and Xite (two 
regulatory noncoding RNA genes of the X-inactivation 
center) and also interacts with Ctcf (the X-chromosome 
inactivation trans-factor) to regulate X-chromosome 
pairing and counting [71]. Th  ese studies expanded our 
knowledge of the Oct4-centered transcriptional regula-
tory network in pluri  potent cells, and their results have 
elucidated new mechanisms associated with establishing 
and maintain  ing pluripotency.
Taken together, Oct4 interacts with other pluripotency 
factors – such as Nanog, Sox2, Sall4, Klf5, Zfp143, 
Zfp206, Esrrb, Dax1 and Tcfcp2l1 – to form auto-
regulatory and cross-regulatory loops and to maintain a 
pluripotent state. Interestingly, some of these factors, 
including Esrrb, Tcfcp2l1 and Dax1, depend on Oct4 for 
the eﬃ   cient targeting of several of their shared sites [41], 
emphasizing the importance of coordination among 
pluripotency factors and the critical role of Oct4 in the 
maintenance of a pluripotent state. Additionally, Oct4 
may recruit transcriptional repressive complexes, such as 
NuRD and PRC1, to the genomic sites of lineage-speciﬁ  c 
factors and prevent diﬀ   erentiation of pluripotent cells 
(Figure 2).
Indispensable role of Oct4 in reprogramming
Th  e achi    evement of reprogramming by four deﬁ  ned 
transcription factors drew tremendous interest in the 
scientiﬁ  c ﬁ  eld. Th   e earliest reprogramming was achieved 
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[2] or the Th  omson factors (Oct4, Sox2, Nanog and 
Lin28) [3], both of which include Oct4. It was later found 
that some cell types express one or several reprogram-
ming factors endogenously and require fewer factors for 
reprogramming. Other factors and some family members 
of reprogramming factors, as well as certain chemicals, 
promote the reprogramming process (reviewed in [23]). 
Noticeably, Oct4 was required in all except two studies to 
derive induced pluripotent stem (iPS) cell lines: one study 
found that BIX-01294, an inhibitor of the G9a histone 
methyltransferase, could reprogram mouse neural pro-
genitor cells in concert with Sox2, Klf4 and c-Myc [72]; 
the other study found that Nr5a2 and its close family 
member Nr5a1 could replace Oct4 in the reprogramming 
of mouse embryonic ﬁ  broblasts [73]. Th  e eﬃ   ciency of 
reprogramming was extremely low in both reports, 
however, and these substitutes might function through 
modulating  Oct4 and Nanog expression. In addition, 
Fbx15 (a marker gene of undiﬀ  erentiated ESCs that is 
dispensable for pluripotency in ESCs) was utilized as a 
reporter of reprogramming in the ﬁ  rst generation of iPS 
cells. Th   e derived iPS cell lines, however, were dissimilar 
to ESCs in several aspects and could not generate 
chimeras [2]. Further characterization of these lines 
found that the promoter of the endogenous Oct4 gene 
was still highly methylated. In later research, the state of 
the hypomethylated Oct4 promoter was used as an 
indicator of complete reprogramming, and the resultant 
iPS cell lines could not be distinguished from ESCs, 
further emphasizing the importance of Oct4 in regaining 
pluripotency [74]. Moreover, the derivation of iPS cell 
lines requires viral transfection, hampering their clinical 
application; one way of avoiding this problem is to use 
fewer reprogramming factors. Scholer’s group success-
fully reprogrammed both mouse and human neural 
progenitors using only Oct4 [75,76], again highlighting 
the power of Oct4 in re-establishing pluripotency.
Having demonstrated the essential and critical role of 
Oct4 in regaining pluripotency, scientists have engaged 
Figure 2. Oct4 interacts with various partners and regulates diff  erent target sets to carry out its functions. Depending on its associated 
partners, Oct4 can either activate or repress its target genes. When associated with factors such as Sox2, Nanog and Sall4 at regulatory elements, 
Oct4 usually exerts stimulatory eff  ects on gene expression. Additionally, Oct4 can repress developmental genes through interacting with 
repressors (for example, NuRD and PRC1). Through regulating various targets, Oct4 has versatile eff  ects on pluripotency: it maintains self-renewal 
and pluripotency by activating its own expression and that of factors such as Sox2 and Nanog; through modulating the expression or function 
of development-associated genes – such as Stk40, Cdx2, Eset and FoxD3 – Oct4 prevents the diff  erentiation of pluripotent stem cells; it can also 
infl  uence other aspects of embryonic stem cells (ESCs), including cell cycle and X-chromosome inactivation, through various eff  ectors (for example, 
miR-302a, Ctcf). ExEn, extraembryonic endoderm.
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mechanisms of reprogramming, especially the roles of 
Oct4 during the process of reprogramming. Preliminary 
results showed that Oct4 plays an important role in 
activating ESC-speciﬁ  c genes by cooperating with Sox2 
and Klf4, and most of these genes are silenced in partially 
reprogrammed cells [77]. Moreover, Oct4 was reported 
to suppress the transcription of the epithelial mesen-
chymal transition mediator Snail to facilitate reprogram-
ming [78]. Interestingly, a new strategy for Oct4 functions 
was recently suggested – that is, Oct4 speciﬁ  cally 
interacts with nuclear β-catenin and facilitates its pro-
teasomal degradation, thus maintaining the undiﬀ  eren-
tiated state of ESCs [79]. Th   e important conclusions from 
these studies are that Oct4 does not function alone and 
that a delicate balance among pluripotency factors 
deﬁ  nes the state of pluripotency in ESCs and embryonic 
cells. Similarly, regaining this balance is the key to 
successful reprogramming, which might, at least partially, 
explain why reprogramming eﬃ   ciency is very low, even 
when four factors are eﬃ   ciently transduced into somatic 
cells.
Conclusion and perspective
Since Oct4 was ﬁ  rst identiﬁ  ed in mice as an embryonic 
stem cell-speciﬁ   c and germline-speciﬁ  c  transcription 
factor in 1990, studies have highlighted its importance in 
governing pluripotency. Th   e complex regulation of Oct4 
expression further reﬂ   ects the necessity to control its 
expression level precisely. Th   e interest in Oct4 increases 
primarily due to the indispensable role of Oct4 in the 
generation of iPS cells. Nevertheless, a number of 
important issues remain to be addressed.
Th  e study of gene expression proﬁ  ling indicates that 
Oct4 primarily acts as an activator of gene expression 
[59]. In Oct4 protein interactomes, however, many Oct4-
associated partners have been identiﬁ   ed as trans  crip-
tional repressors [41,42,66,67]. Notably, the coactivator 
p300 was found to be recruited to the cluster of Oct4, 
Sox2 and Nanog using a chromatin immunoprecipitation-
seq approach [61], implying that p300 might play a role in 
Oct4-mediated transcription activation. Strangely, none 
of the recently identiﬁ   ed Oct4-centered protein inter-
action networks contain p300.
How Oct4 connects to the basal transcriptional 
machinery also remains unclear. Van den Berg and 
colleagues showed the association of Esrrb with compo-
nents of the basal transcriptional machinery, including 
the mediator complex, RNA polymerase II subunits and 
TATA box binding protein plus transcription-associated 
factors. Th  e connection between Oct4 and the basal 
transcriptional machinery could thus be established 
through Esrrb, as the association of Oct4 with Esrrb has 
been documented [56].
Furthermore, it remains unclear how diﬀ  erent dosages 
of Oct4 act to determine ESC fates. One possibility is that 
Oct4 associates with distinct partners at diﬀ  erent 
dosages, provided that Oct4 displays diﬀ  erent aﬃ   nities 
toward its partners at diﬀ  erent expression levels. Achiev-
ing a comprehensive understanding of how diﬀ  erent 
biological processes, such as transcriptional, post-
transcrip  tional and epigenetic regulation, work together 
to maintain Oct4 at an appropriate level will also help to 
solve this puzzle. Another interesting and important 
question is why Oct4 expression is so critical in 
generating fully reprogrammed cells from somatic cells.
Clearly, the investigation of how Oct4 exerts its 
functions through regulating various targets is in its early 
stages, and this should be the focus of future research. In 
addition, employing an experimental design to study 
Oct4-associated proteins or target genes at a single-cell 
level in a dynamic manner will allow us to obtain a clearer 
picture of how Oct4 maintains and re-establishes 
pluripotency. We believe that these types of investigations 
and other related studies will fulﬁ  ll the great promise of 
pluripotent stem cells in the near future.
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